Establishment of a humanized mouse model of keloid diseases following the migration of patient immune cells to the lesion: Patient-derived keloid xenograft (PDKX) model
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders.
Abstract
Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders.
참고문헌 (40)
- Tan, S., "Understanding keloid pathobiology from a quasineoplastic perspective : less of a scar and more of a chronic inflammatory disease with cancer-like tendencies", Front. Immunol, 10, pp.1810~ (2019)
- Ud-Din, S., "New insights on keloids, hypertrophic scars, and striae", Dermatol. Clin, 32, pp.193~209 (2014)
- Shih, B., "Genetics of keloid scarring", Arch. Dermatol. Res, 302, pp.319~339 (2010)
- Sandulache, V. C., "Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor(TGF)-beta1-induced collagen synthesis", Wound Repair Regen, 15, pp.122~133 (2007)
- Lee, S. Y., "IL-17 induced stromal cell-derived factor-1 and profibrotic factor in keloid-derived skin fibroblasts via the STAT3 pathway", Inflammation, 43, pp.664~672 (2020)
- Shetlar, M. R., "The use of athymic nude mice for the study of human keloids", Proc. Soc. Exp. Biol. Med, 179, pp.549~552 (1985)
- Shetlar, M. R., "Implants of keloid and hypertrophic scars into the athymic nude mouse : changes in the glycosaminoglycans of the implants", Connect. Tissue Res, 26, pp.23~36 (1991)
- Kischer, C. W., "Implants of hypertrophic scars and keloids into the nude(athymic)mouse : viability and morphology", J. Trauma, 29, pp.672~677 (1989)
- Waki, E. Y., "Effects of pharmacologic agents on human keloids implanted in athymic mice. A pilot study", Arch. Otolaryngol. Head Neck Surg, 117, pp.1177~1181 (1991)
- Tang, Z., "Wubeizi ointment suppresses keloid formation through modulation of the mTOR pathway", Biomed. Res. Int, 2020, pp.3608372~ (2020)
- Ishiko, T., "Chondroitinase injection improves keloid pathology by reorganizing the extracellular matrix with regenerated elastic fibers", J. Dermatol, 40, pp.380~383 (2013)
- Herndon, D., "Reduced postburn hypertrophic scarring and improved physical recovery with yearlong administration of oxandrolone and propranolol", Ann. Surg, 268, pp.431~441 (2018)
- Lemaire, R., "Resolution of skin fibrosis by neutralization of the antifibrinolytic function of plasminogen activator inhibitor 1", Arthritis Rheumatol, 68, pp.473~483 (2016)
- Lee, S. Y., "IL-17 Induces autophagy dysfunction to promote inflammatory cell death and fibrosis in keloid fibroblasts via the STAT3 and HIF-1alpha dependent signaling pathways", Front. Immunol, 13, pp.888719~ (2022)
- Lei, L., "Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis", Clin. Exp. Rheumatol, 34, pp.14~22 (2016)
- Hammerich, L., "Role of IL-17 and Th17 cells in liver diseases", Clin. Dev. Immunol, 2011, pp.345803~ (2011)
- Pignatti, P., "Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis", Am. J. Respir. Crit. Care Med, 173, pp.310~317 (2006)
- Nirodi, C. S., "Chemokine and chemokine receptor expression in keloid and normal fibroblasts", Wound Repair Regen, 8, pp.371~382 (2000)
- Nangole, F. W., "Multiple cytokines elevated in patients with keloids : is it an indication of auto-inflammatory disease?", J. Inflamm. Res, 14, pp.2465~2470 (2021)
- Steinmetz, O. M., "CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis", J. Immunol, 183, pp.4693~4704 (2009)
- Friedman, D. W., "Regulation of collagen gene expression in keloids and hypertrophic scars", J. Surg. Res, 55, pp.214~222 (1993)
- Pan, X., "Transforming growth factor beta1induces the expression of collagen type I by DNA methylation in cardiac fibroblasts", PLoS ONE, 8, pp.e60335~ (2013)
- Jagadeesan, J., "Transforming growth factor beta(TGFbeta)and keloid disease", Int. J. Surg, 5, pp.278~285 (2007)
- Seo, B. F., "Models of abnormal scarring", Biomed. Res. Int, 2013, pp.423147~ (2013)
- Supp, D. M., "Animal models for studies of keloid scarring", Adv. Wound Care (New Rochelle), 8, pp.77~89 (2019)
- Choi, M. H., "A selective small-molecule inhibitor of c-Met suppresses keloid fibroblast growth in vitro and in a mouse model", Sci. Rep, 11, pp.5468~ (2021)
- Syed, F., "Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites : clinical implications for lesional site-directed therapy", Br. J. Dermatol, 164, pp.83~96 (2011)
- Ashcroft, K. J., "Site-specific keloid fibroblasts alter the behaviour of normal skin and normal scar fibroblasts through paracrine signalling", PLoS ONE, 8, pp.e75600~ (2013)
- Walsh, N. C., "Humanized mouse models of clinical disease", Annu. Rev. Pathol, 12, pp.187~215 (2017)
- King, M. A., "Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex", Clin. Exp. Immunol, 157, pp.104~118 (2009)
- Tary-Lehmann, M., "Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood", J. Exp. Med, 175, pp.503~516 (1992)
- Li, Y., "The polygenic map of keloid fibroblasts reveals fibrosis-associated gene alterations in inflammation and immune responses", Front. Immunol, 12, pp.810290~ (2021)
- Shin, J. U., "TSLP is a potential initiator of collagen synthesis and an activator of CXCR4", SDF-1 axis in keloid pathogenesis, 2016, pp.136, 507~515
- Wang, Z. C., "The roles of inflammation in keloid and hypertrophic scars", Front. Immunol, 11, pp.603187~ (2020)
- Zhang, J., "IL-17 promotes scar formation by inducing macrophage infiltration", Am. J. Pathol, 188, pp.1693~1702 (2018)
- Zhang, Q., "Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17", IL-6 axis, 2009, pp.4, e7798~
- Tesch, G. H., "MCP-1", CCL2 : a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy, 2008, pp.294, F697~F701
- Marra, F., "Renaming cytokines : MCP-1, major chemokine in pancreatitis", Gut, 54, pp.1679~1681 (2005)
- Xia, Y., "MCP-1", CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy, 2007, pp.6, 101~107
- Kischer, C. W., "Use of nude(athymic)mice for the study of hypertrophic scars and keloids : vascular continuity between mouse and implants", Anat. Rec, 225, pp.189~196 (1989)